WHAT IS CLAIMED IS:

1. Use of an effective amount of a compound in the manufacture for a medicament for treating breast cancer in a subject, wherein the compound is Compound (A), or a pharmaceutically acceptable salt thereof, has the structure:



(A); and

wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ERα), wherein the mutation is selected from the group consisting of: ~~K303R, D538G,~~ Y537S~~, E380Q, Y537C, Y537N, A283V, A546D, A546T, A58T, A593D, A65V, C530L, D411H, E279V, E471D, E471V, E523Q, E542G, F461V, F97L, G145D, G160D, G274R, G344D, G420D, G442R, G557R, H524L, K252N, K481N, K531E, L370F, L453F, L466Q, L497R, L536H,~~ and L536P~~, L536Q, L536R, L540Q, L549P, M388L, M396V, M421V, M437I, M522I, N156T, N532K, N69K, P147Q, P222S, P535H, R233G, R477Q, R503W, R555H, S282C, S329Y, S338G, S432L, S463P, S47T, S576L, V392I, V418E, V478L, V533M, V534E, Y537D and Y537H~~.

~~2. The use of Claim 1, wherein the breast cancer has a Y537S mutation.~~

~~3. The use of Claim 1, wherein the breast cancer has a L536P mutation.~~

~~4.~~2. The use of ~~any one of Claims 1-3~~Claim 1, wherein the breast cancer is ER positive breast cancer.

~~5.~~3. The use of ~~any one of Claim 1-3~~Claim 1, wherein the breast cancer is ER positive/HER2-negative breast cancer.

~~6.~~4. The use of any one of Claims 1-~~5~~3, wherein the breast cancer is local breast cancer, metastatic breast cancer and recurrent breast cancer.

~~7. The use of any one of Claims 1-5, wherein the breast cancer is metastatic breast cancer.~~

~~8. The use of any one of Claims 1-7, wherein the breast cancer is recurrent breast cancer.~~

~~9.~~5. The use of any one of Claims 1-~~8~~4, wherein the subject has been previously treated with an endocrine therapy.

~~10.~~6. The use of Claim ~~9~~5, wherein the treatment was with a selective ER modulator (SERM).

~~11.~~7. The use of Claim ~~10~~6, wherein the selective ER modulator is selected from the group consisting of tamoxifen, raloxifene, ospemifene, bazedoxifene, toremifene and lasofoxifene.

~~12.~~8. The use of Claim ~~9~~5, wherein the treatment was with a selective ER degrader (SERD).

~~13.~~9. The use of Claim ~~12~~8, wherein the selective ER degrader is selected from the group consisting of fulvestrant, elacestrant, (E)-3-[3,5-Difluoro-4-[(1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-1,3,4,9-tetrahydropyrido[3,4-b]indol-1-yl]phenyl]prop-2-enoic acid, (R)-6-(2-(ethyl(4-(2-(ethylamino)ethyl)benzyl)amino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthalen-2-ol, (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid, (E)-3-(4-((2-(2-(1,1-difluoroethyl)-4-fluorophenyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)acrylic acid, (E)-3-(4-((2-(4-fluoro-2,6-dimethylbenzoyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenyl)acrylic acid, (S)-8-(2,4-dichlorophenyl)-9-(4-((1-(3-fluoropropyl)pyrrolidin-3-yl)oxy)phenyl)-6,7-dihydro-5H-benzo[7]annulene-3-carboxylic acid and~~/or~~ 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol.

~~14.~~10. The use of Claim ~~9~~5, wherein the treatment was with an aromatase inhibitor.

~~15.~~11. The use of Claim ~~14~~10, wherein the aromatase inhibitor is a steroidal aromatase inhibitor.

~~16. The use of Claim 15, wherein the steroidal aromatase inhibitor is selected from the group consisting of exemestane and testolactone.~~

~~17.~~12. The use of Claim ~~14~~10, wherein the aromatase inhibitor is a non-steroidal aromatase inhibitor.

~~18.~~13. The use of Claim ~~17~~10, wherein the ~~non-steroidal~~ aromatase inhibitor is selected from the group consisting of exemestane, testolactone, anastazole and letrazole.

~~19.~~14. The use of any one of Claim 1-~~18~~13, wherein the subject is a woman.

~~20.~~15. The use of Claim ~~19~~14, wherein the subject is a premenopausal woman.

~~21.~~16. The use of Claim ~~19~~14, wherein the subject is a perimenopausal woman.

~~22.~~17. The use of Claim ~~19~~14, wherein the subject is a menopausal woman.

~~23.~~18. The use of Claim ~~19~~14, wherein the subject is a postmenopausal woman.

~~24.~~19. The use of any one of Claim 1-~~18~~13, wherein the subject is a man.

~~25.~~20. The use of any one of Claim 1-~~24~~19, wherein the subject has a serum estradiol level in the range of >15 pg/mL to 350 pg/mL.

~~26.~~21. The use of any one of Claim 1-~~24~~19, wherein the subject has a serum estradiol level ≤ 15 pg/mL.

~~27. The use of any one of Claim 1-24, wherein the subject has a serum estradiol level ≤ 10 pg/mL.~~

22. The use of any one of Claims 1-21, wherein the mutation is Y537S.

55981823